Equities analysts forecast that Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) will post earnings of $1.73 per share for the current fiscal quarter, according to Zacks. Seven analysts have provided estimates for Gilead Sciences’ earnings. The highest EPS estimate is $1.86 and the lowest is $1.38. Gilead Sciences reported earnings per share of $2.08 during the same quarter last year, which would suggest a negative year-over-year growth rate of 16.8%. The business is scheduled to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Gilead Sciences will report full-year earnings of $6.51 per share for the current year, with EPS estimates ranging from $6.22 to $6.94. For the next year, analysts expect that the company will report earnings of $6.32 per share, with EPS estimates ranging from $4.97 to $6.85. Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings results on Tuesday, February 1st. The biopharmaceutical company reported $0.69 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.53 by ($0.84). The firm had revenue of $7.24 billion for the quarter, compared to analysts’ expectations of $6.64 billion. Gilead Sciences had a net margin of 22.80% and a return on equity of 45.27%. The firm’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.19 EPS.
In other news, EVP Brett A. Pletcher sold 1,691 shares of the company’s stock in a transaction that occurred on Wednesday, February 9th. The stock was sold at an average price of $63.89, for a total value of $108,037.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brett A. Pletcher sold 3,634 shares of the stock in a transaction that occurred on Friday, March 11th. The stock was sold at an average price of $58.24, for a total value of $211,644.16. The disclosure for this sale can be found here. Insiders sold 19,386 shares of company stock valued at $1,283,423 over the last 90 days. Company insiders own 0.16% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Wolf Group Capital Advisors grew its position in Gilead Sciences by 200.0% in the fourth quarter. Wolf Group Capital Advisors now owns 128,271 shares of the biopharmaceutical company’s stock worth $9,314,000 after acquiring an additional 85,514 shares during the period. U.S. Capital Wealth Advisors LLC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $8,758,000. Cpwm LLC grew its stake in shares of Gilead Sciences by 24.6% in the third quarter. Cpwm LLC now owns 31,240 shares of the biopharmaceutical company’s stock valued at $2,182,000 after buying an additional 6,163 shares in the last quarter. WBI Investments Inc. grew its stake in shares of Gilead Sciences by 10.4% in the fourth quarter. WBI Investments Inc. now owns 46,422 shares of the biopharmaceutical company’s stock valued at $3,249,000 after buying an additional 4,371 shares in the last quarter. Finally, Meyer Handelman Co. grew its stake in shares of Gilead Sciences by 0.9% in the third quarter. Meyer Handelman Co. now owns 423,424 shares of the biopharmaceutical company’s stock valued at $29,576,000 after buying an additional 3,900 shares in the last quarter. Institutional investors own 79.00% of the company’s stock.
Shares of GILD stock opened at $61.82 on Tuesday. The stock has a market cap of $77.52 billion, a PE ratio of 12.54, a price-to-earnings-growth ratio of 0.44 and a beta of 0.40. The business has a 50-day simple moving average of $60.52 and a 200-day simple moving average of $66.17. The company has a quick ratio of 1.13, a current ratio of 1.27 and a debt-to-equity ratio of 1.24. Gilead Sciences has a 52-week low of $57.19 and a 52-week high of $74.12.
The business also recently declared a quarterly dividend, which was paid on Wednesday, March 30th. Stockholders of record on Tuesday, March 15th were given a $0.73 dividend. The ex-dividend date was Monday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.71. This represents a $2.92 dividend on an annualized basis and a dividend yield of 4.72%. Gilead Sciences’s dividend payout ratio is 59.23%.
Gilead Sciences Company Profile (Get Rating)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- Array Technologies Stock Giving Another Ground Floor Entry
- UiPath Stock is Nearing Rock Bottom Down Here
- 3 Undervalued S&P 500 Stocks to Buy Now
- 3 Undervalued Easter Eggs to Watch For This Earnings Season
- Lululemon Rises On Wave Of Price Target Increases
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.